Vanrafia Patent Expiration

Vanrafia is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 7 US drug patents filed in 2025 out of which none have expired yet. Vanrafia's patents will be open to challenges from 02 April, 2029. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 16, 2040. Details of Vanrafia's patents and their expiration are given in the table below.

Filter patents by

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11491137 Methods of improving renal function
Dec, 2040

(15 years from now)

Active
US11998526 Methods of improving renal function
Dec, 2040

(15 years from now)

Active
US12121509 Methods of improving renal function
Dec, 2040

(15 years from now)

Active
US10016393 Stabilized pharmaceutical dosage forms comprising atrasentan
Jul, 2034

(9 years from now)

Active
US9364458 Stabilized pharmaceutical dosage forms comprising atrasentan
Jul, 2034

(9 years from now)

Active
US11874283 Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
Feb, 2032

(6 years from now)

Active
US8623819 Therapy for complications of diabetes
Aug, 2028

(3 years from now)

Active


FDA has granted several exclusivities to Vanrafia. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vanrafia, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vanrafia.

Exclusivity Information

Vanrafia holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Vanrafia's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 02, 2030

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Vanrafia is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vanrafia's family patents as well as insights into ongoing legal events on those patents.

Vanrafia's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Vanrafia's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 16, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Vanrafia Generics:

There are no approved generic versions for Vanrafia as of now.

Alternative Brands for Vanrafia

There are several other brand drugs in the same treatment category as Vanrafia. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Novartis
Fabhalta





About Vanrafia

Vanrafia is a drug owned by Novartis Pharmaceuticals Corp. Vanrafia uses Atrasentan Hydrochloride as an active ingredient. Vanrafia was launched by Novartis in 2025.

Approval Date:

Vanrafia was approved by FDA for market use on 02 April, 2025.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Vanrafia is 02 April, 2025, its NCE-1 date is estimated to be 02 April, 2029.

Active Ingredient:

Vanrafia uses Atrasentan Hydrochloride as the active ingredient. Check out other Drugs and Companies using Atrasentan Hydrochloride ingredient

Dosage:

Vanrafia is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.75MG BASE TABLET Prescription ORAL